Fabentech’s polyclonal antibody technology chosen by the European Commission to counter CBRN threats within the framework of the Counteract consortium
FABENTECH is the only French SME chosen to be a part of the COUNTERACT European consortium, which aims to develop medical countermeasures targeting Chemical, Biological, Radiological and Nuclear (CBRN) threats Funded by the European Defence Fund and coordinated by the French Alternative Energies and Atomic Energy Commission (CEA), the consortium includes 26 partners from 11 …
